Heyholder
‹ Activism Filings

Genome&Company Q3 revenue KRW 7.2 billion, loss from main business KRW 7.5 billion

Genome&Company· Periodic Report

AI summary · Not investment advice

Genome & Company sold KRW 7.2 billion in Q3 and lost KRW 7.5 billion from its main business; sales rose 10.4% from a year earlier and 15.8% from the prior quarter.

Operating profit · 3 months

KRW -7.5 billion

Key facts

Revenue (3 months)
KRW 7.2 billion
Net income (3 months)
KRW -8.4 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 6.6 billion
Revenue (year to date)
KRW 19.3 billion
Operating profit (prior-year 3 months)
KRW -8.1 billion
Operating profit (year to date)
KRW -21.5 billion
Net income (prior-year 3 months)
KRW -8.0 billion
Net income (year to date)
KRW -57.9 billion

Commentary

AI commentary · Not investment advice

What happened

Genome & Company filed its quarterly report on a consolidated basis for the third quarter. Sales for the latest 3 months were KRW 7,238,987,085. Sales for the same 3 months a year earlier were KRW 6,557,558,334.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 7,454,269,238. A year earlier it was a loss of KRW 8,089,713,959. Net income (final profit after taxes and other costs) for the latest 3 months was a loss of KRW 8,429,516,400. A year earlier it was a loss of KRW 8,043,803,904.

What changes for shareholders

For the year to date, sales were KRW 19,275,010,167. Operating profit was a loss of KRW 21,523,834,838. Net income was a loss of KRW 57,888,402,904.

Sales for the latest 3 months rose 10.4% from a year earlier. They rose 15.8% from the previous quarter.

Comments

No comments yet

Comments from shareholders will appear here.